EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
2014 · Oncotarget · 382 citations
https://doi.org/10.18632/oncotarget.2608
Y
Yuxiang Ma
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
254
Papers
6.0K
Citations
41
h-index
114
i10-index
Yuxiang Ma is an academic researcher from North China Electric Power University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 41, co-authored 216 publications.
ORCID: 0000-0003-1173-8441Papers by this author
worksRatio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer
2015 · Scientific Reports · 160 citations
https://doi.org/10.1038/srep10481
Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy
2015 · Theranostics · 73 citations
https://doi.org/10.7150/thno.10084
Typically inhibiting USP14 promotes autophagy in M1-like macrophages and alleviates CLP-induced sepsis
2020 · Cell Death and Disease · 52 citations
https://doi.org/10.1038/s41419-020-02898-9
Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer
2021 · BMC Medicine · 50 citations
https://doi.org/10.1186/s12916-021-02089-z
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
2023 · Journal of Hematology & Oncology · 41 citations
https://doi.org/10.1186/s13045-023-01445-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat